Levobupivacaine Molteni (Levobupivacaine)

Levobupivacaine blocks voltage‑gated sodium channels on neuronal membranes, stabilising them in an inactive state. This inhibition prevents sodium influx, stopping the initiation and propagation of nerve impulses and resulting in a reversible loss of sensation.

The dose of Levobupivacaine Molteni is determined by the prescribing clinician based on the type of procedure, route of administration, patient weight, age and overall health. Specific dosing regimens are not provided here and must follow the prescriber’s order.

Safety data for levobupivacaine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under the guidance of a qualified healthcare professional.

To order Levobupivacaine Molteni, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Both are amide‑type local anesthetics, but levobupivacaine is often preferred when a safer cardiac profile is desired.

Levobupivacaine Molteni should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture and extreme temperature fluctuations to maintain potency and sterility.

Levobupivacaine is administered by a qualified professional via epidural, intrathecal or infiltration injection. The route and technique are selected according to the clinical indication, and the injection is performed under aseptic conditions with appropriate monitoring.

Serious risks include cardiac arrest, severe arrhythmias, seizures, and anaphylactic reactions. Early signs of systemic toxicity such as tinnitus, metallic taste, or circumoral numbness should prompt immediate assessment and supportive measures.

Levobupivacaine is contraindicated in patients with a known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, and individuals in whom an intravascular injection cannot be reliably avoided.